AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cytosolic carboxypeptidase-like protein 5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8NDL9

UPID:

CBPC5_HUMAN

Alternative names:

ATP/GTP-binding protein-like 5; Protein deglutamylase CCP5

Alternative UPACC:

Q8NDL9; A2VDI7; B7WPG9; B7Z7I7; D6W548; Q53SW0; Q53SZ0; Q96IK8; Q9H6V0; Q9H8P8

Background:

Cytosolic carboxypeptidase-like protein 5, also known as Protein deglutamylase CCP5 and ATP/GTP-binding protein-like 5, plays a crucial role in cellular processes by mediating the deglutamylation of tubulin and non-tubulin target proteins. This enzyme is pivotal in the removal of polyglutamate side chains from the C-terminal tail of alpha- and beta-tubulin, facilitating proper cellular function and response.

Therapeutic significance:

The association of Cytosolic carboxypeptidase-like protein 5 with Retinitis pigmentosa 75, a retinal dystrophy, underscores its therapeutic significance. Understanding the role of this protein could open doors to potential therapeutic strategies for treating this and possibly other related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.